~~<i id='5558DCA3E7'><strike id='5558DCA3E7'><tt id='5558DCA3E7'><pre id='5558DCA3E7'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

fashion

author：fashion 2025-09-05 11:26:21 - browse：4512

Alkermes shareholders voted Thursday to re-elect all of the drugmaker’s current directors, ending an acrimonious proxy fight with hedge fund Sarissa Capital Management, which had sought to seat three directors on the board.

At the company’s annual meeting, shareholders voted in favor of Alkermes’ proposal to retain all seven of the director nominees to the 11-person board.

The outcome is a setback for Sarissa, which owns 8.5% of Alkermes and is run by activist investor Alex Denner. Sarissa has accused Alkermes executives of mismanaging the business and destroying shareholder value.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： Dramatically reducing cancer deaths requires the PASTEUR Act

focus

hotspot

knowledge

focus

ThesuperbugStaphylcocusepidermidisisshownonanagarplate.Morethan3millionAmericansdevelopadrug-resista

WSS

CDC: Uninsured rate hit 'record low' right as states cut Medicaid

Who is Magistrate Judge Moxila Upadhyaya in Trump's Jan. 6 case?

OTC birth control: A brief history of over the counter pill design

He's a Nobel laureate. Critics say he was misleading on Covid

STAT readers on older presidents, polypills, Medicare, and more

STAT readers on older presidents, polypills, Medicare, and more

hotspot

fashion

focus

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Antivenom research: Lessons from HIV applied in search for universal antidote

Medicare proposal to cover medical devices draws a mixed reaction

ProMED, early warning system on disease outbreaks, in peril

The high cost of giving birth even with insurance

Alabama frozen embryo ruling has major implications for IVF clinics

Apple is now the first public company to be valued at $3 trillion

Medicare inequities exacerbate Puerto Rico’s health disparities

Medical leaders decry Supreme Court decision on affirmative action

'Ancient DNA,' 23andMe reveal African American ancestries

focus

Alabama hospital puts IVF treatments on hold

6 phony surgeries that take placebo to the extreme

The drug industry sees a key ally in the Senate prevail

PBM reform efforts get punted in Congress

ProMED, early warning system on disease outbreaks, in peril

STAT readers on older presidents, polypills, Medicare, and more

focus

hotspot

knowledge

focus